SciSparc Subsidiary Files International Patent for Novel Weight Loss, Fatty Liver Therapy
Summary
SciSparc's majority-owned subsidiary, NeuroThera Labs, announced the publication of an international patent application (PCT) in collaboration with Clearmind Medicine. The patent covers a novel combination therapy (MEAI-PEA) aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD). This development follows recent corporate actions, including a reverse stock split earlier this month and NeuroThera Labs' acquisition of a majority stake in CliniQu, representing a positive step in the company's R&D pipeline. The therapy is positioned as a potentially safer, easier, and more cost-effective alternative to GLP-1 agonists in a rapidly growing market, which is projected to reach $226 billion by 2035. For a micro-cap company like SciSparc, this patent publication, even at an early stage, signals progress in developing valuable intellectual property and potential future revenue streams. Investors will be watching for future clinical trial progress and further patent grants.
At the time of this announcement, SPRC was trading at $4.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $3.60 to $94.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.